What is the latest PRSMJOHNSN stock price?
The latest stored price for PRSMJOHNSN is Rs 97.48 as of 2026-11-03.
gimli
PRSMJOHNSN stock AI analysis
PRSMJOHNSN Stock AI Analysis: Price, PE, 50DMA, Shareholding and Peers
PRISM JOHNSON LIMITED is a small-cap stock in Construction Materials. This Gimli page shows the latest available PRSMJOHNSN price, returns, 50DMA/200DMA trend, PE, ROE, ROCE, financials, shareholding pattern, and industry peers for Indian stock screening research.
Price
₹97.48
1W return
+1.98%
1M return
-5.92%
3M return
-10.47%
6M return
-27.17%
1Y return
-32.67%
Market cap
₹4,906.72 cr
PE
36.21
PB
2.67
ROE
+7.51%
ROCE
+12.35%
RSI
41.72
Turnover
₹0.99 cr
Why it can matter in screens
- Momentum: PRSMJOHNSN is below 50DMA, below 200DMA; RSI is 41.72.
- Returns: 1D -0.28%, 1W +1.98%, 1M -5.92%, 3M -10.47%, 1Y -32.67%.
- Trend levels: 52W high ₹131.00, 52W low ₹93.76, off high -25.59%.
- Liquidity: latest turnover is ₹0.99 cr; volume vs 20D is +0.69%.
- Valuation/profitability: PE 36.21, PB 2.67, ROE +7.51%, ROCE +12.35%.
- Growth: 3Y sales CAGR +0.54%, 3Y profit CAGR n/a.
Quick Answers
Is PRSMJOHNSN above its 50DMA and 200DMA?
PRSMJOHNSN is below 50DMA, below 200DMA. The latest 50DMA is 106.34 and the latest 200DMA is 117.43.
What are PRSMJOHNSN PE, ROE and ROCE?
PRSMJOHNSN has PE 36.21, ROE +7.51%, and ROCE +12.35% in Gimli's latest available snapshot.
How has PRSMJOHNSN performed recently?
PRSMJOHNSN has returned -5.92% over 1 month, -10.47% over 3 months, and -32.67% over 12 months in the latest stored data.
Is this stock page investment advice?
No. This page is a data snapshot for screening and research. It is not buy, sell, legal, tax, or investment advice.
Financials and Ownership
Quarterly income statement
| Period | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-06-30 | 1,840.62 cr | 235.48 cr | 93.97 cr | 2.07 |
| 2026-03-31 | 2,091.62 cr | 189.09 cr | -22.38 cr | 0.13 |
| 2025-12-31 | 1,810.04 cr | 257.77 cr | 61.12 cr | 1.21 |
| 2025-09-30 | 1,826.75 cr | 200.11 cr | 2.81 cr | 0.06 |
| 2025-06-30 | 1,895.37 cr | 179.44 cr | 2.54 cr | 0.05 |
| 2025-03-31 | 1,948.92 cr | 363.79 cr | 129.30 cr | 2.57 |
| 2024-12-31 | 1,792.19 cr | 143.73 cr | n/a | nan |
| 2024-09-30 | 1,638.86 cr | 62.92 cr | n/a | -1.78 |
Annual income statement
| Year | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-03-31 | 7,326.00 cr | 861.50 cr | 72.90 cr | 1.45 |
| 2025-03-31 | 6,780.46 cr | 755.81 cr | 79.93 cr | 1.59 |
| 2024-03-31 | 7,331.29 cr | 770.54 cr | 181.11 cr | 3.60 |
| 2023-03-31 | 7,209.54 cr | 389.56 cr | -103.23 cr | -2.05 |
| 2022-03-31 | 5,660.40 cr | 571.50 cr | 133.25 cr | nan |
Balance sheet
| Period | Assets | Cash | Debt | Equity |
|---|---|---|---|---|
| 2026-03-31 | 7,332.74 cr | 476.70 cr | 1,421.11 cr | 1,840.92 cr |
| 2025-03-31 | 7,317.86 cr | 407.98 cr | 1,496.57 cr | 1,768.06 cr |
| 2024-03-31 | 7,089.48 cr | 436.01 cr | 1,739.00 cr | 1,643.43 cr |
| 2023-03-31 | 6,556.05 cr | 261.99 cr | 1,656.07 cr | 1,462.76 cr |
| 2022-03-31 | 6,457.02 cr | 257.05 cr | 1,745.99 cr | 1,595.54 cr |
Cash flow
| Period | OCF | FCF | Cash change |
|---|---|---|---|
| 2026-03-31 | 502.89 cr | 144.88 cr | n/a |
| 2025-03-31 | 737.28 cr | 348.39 cr | n/a |
| 2024-03-31 | 472.81 cr | -22.37 cr | n/a |
| 2023-03-31 | 591.86 cr | 222.76 cr | n/a |
| 2022-03-31 | 572.71 cr | 205.02 cr | n/a |
Shareholding Trend
| Period | Promoter | FII/FPI | DII | MF | Retail | Pledge |
|---|---|---|---|---|---|---|
| 2026-06-30 | +74.87% | +2.74% | +6.45% | +6.45% | +15.94% | +0.00% |
| 2026-03-31 | +74.87% | +3.55% | +6.05% | +5.99% | +15.53% | +0.00% |
| 2025-12-31 | +74.87% | +3.53% | +6.23% | +6.00% | +15.37% | +0.00% |
| 2025-09-30 | +74.87% | +3.47% | +6.08% | +6.08% | +15.57% | +0.00% |
| 2025-06-30 | +74.87% | +3.42% | +5.62% | +5.62% | +16.09% | +0.00% |
| 2025-03-31 | +74.87% | +3.42% | +5.57% | +5.57% | +16.14% | +0.00% |
| 2024-12-31 | +74.87% | +3.76% | +5.32% | +5.32% | +16.05% | +0.00% |
| 2024-09-30 | +74.87% | +3.68% | +6.02% | +6.02% | +15.42% | +0.00% |
| 2024-06-30 | +74.87% | +3.63% | +5.94% | +5.94% | +15.56% | +0.00% |
| 2024-03-31 | +74.87% | +3.87% | +5.05% | +5.05% | +16.21% | +0.00% |
| 2023-12-31 | +74.87% | +3.90% | +5.11% | +5.10% | +16.12% | +0.00% |
| 2023-09-30 | +74.87% | +3.72% | +4.85% | +4.85% | +16.55% | +0.00% |
| 2023-06-30 | +74.87% | +3.59% | +4.64% | +4.64% | +16.90% | +0.00% |
| 2023-03-31 | +74.87% | +3.50% | +4.37% | +4.37% | +17.25% | +0.00% |
| 2022-12-31 | +74.87% | +3.47% | +4.11% | +4.11% | +17.55% | +0.00% |
| 2022-09-30 | +74.87% | +3.42% | +4.34% | +4.33% | +17.37% | +0.00% |
| 2022-06-30 | +74.87% | +0.00% | +8.80% | n/a | n/a | +0.00% |
| 2022-03-31 | +74.87% | +0.00% | +9.51% | n/a | n/a | +0.00% |
| 2021-09-30 | +74.87% | +0.00% | +10.40% | n/a | n/a | +0.00% |
| 2021-06-30 | +74.87% | +0.00% | +10.68% | n/a | n/a | +0.00% |
Industry Peers
| Symbol | Name | Mcap | PE | ROE | 1Y |
|---|---|---|---|---|---|
| ULTRACEMCO | ULTRATECH CEMENT LIMITED | 344,178.43 cr | 39.105808 | +11.39% | -2.09% |
| GRASIM | GRASIM INDUSTRIES LTD | 209,537.41 cr | 31.565206 | +4.05% | +6.56% |
| AMBUJACEM | AMBUJA CEMENTS LTD | 91,664.91 cr | 22.925397 | +5.89% | -36.09% |
| SHREECEM | SHREE CEMENT LIMITED | 86,268.95 cr | 54.483361 | +7.05% | -14.53% |
| JKCEMENT | JK CEMENT LIMITED | 39,287.84 cr | 41.010271 | +14.58% | -13.81% |
| DALBHARAT | DALMIA BHARAT LIMITED | 25,910.37 cr | 52.878300 | +2.75% | -33.65% |
| ACC | ACC LIMITED | 21,972.99 cr | 11.513467 | +9.76% | -37.44% |
| RAMCOCEM | THE RAMCO CEMENTS LIMITED | 17,603.78 cr | 27.337615 | +8.29% | -27.35% |
Try these prompts
- Analyze PRISM JOHNSON with valuation, momentum and industry peers
- Compare PRSMJOHNSN with other Construction Materials stocks
- Show small-cap stocks in Construction Materials above 50DMA with positive 1M return
- Find Construction Materials stocks with improving momentum and reasonable valuation
Related screen ideas
- View Construction Materials stocks
- View small-cap stocks
- Find stocks above 50DMA
- Compare PRSMJOHNSN with other Construction Materials stocks
Data snapshot: 2026-11-03. Not investment advice.